Updated GioTag study data press release

Updated real-world data shows Giotrif ®/Gilotrif® (afatinib) followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLCSequential afatinib and osimertinib was associated with encouraging time on treatment and overall survival in patients with EGFR T790M-positive NSCLC, especially in patients with Del19 mutationUpdated analysis of the observational GioTag study is published today inFuture Oncology
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news